Chronic Heart Failure (CHF)

News

Heart failure is a progressive disease that is caused by the heart being too stiff or weak to pump blood throughout the body. A dysfunction of the sarcomere, the basic contractile unit of the heart, impacts the heart’s ability to properly fill with blood. Ejection fraction, a measure for the ability of the heart to pump blood with each beat, is used to classify heart failure and guide treatment.

Symptoms of heart failure include shortness of breath, fatigue, coughing and a high impact on quality of life to perform daily or physical activities. It is estimated that over 10 million individuals are currently affected by heart failure in China and that the prevalence among Chinese adults aged ≥35 years continues to grow.

There is no cure for heart failure but there are various options to actively manage the disease and slow down progression. Unfortunately, current therapies all have limitations so that heart failure remains a leading cause of hospitalization and readmission in elderly people. Aficamten can potentially serve as a drug candidate for heart failure with preserved ejection fraction (HFpEF). Being a myosin inhibitor, aficamten modulates sarcomere dysfunction by improving cardiac muscle contractility and has the potential to increase lifespan of patients with heart failure. Omecamtiv Mecarbil is a novel, selective cardiac myosin activator for the potential treatment for heart failure with reduced ejection fraction (HFrEF) by increasing cardiac contractility.

For further information about our partner, Cytokinetics, please visit https://cytokinetics.com

Scroll to Top